Pasadena, CALIFORNIA4 Active Studies

Diabetic Retinopathy Clinical Trials in Pasadena, CALIFORNIA

Find 4 actively recruiting diabetic retinopathy clinical trials in Pasadena, CALIFORNIA. Connect with local research sites and explore new treatment options.

4
Active Trials
3
Sponsors
1,188
Enrolling

Recruiting Diabetic Retinopathy Studies in Pasadena

About Diabetic Retinopathy Clinical Trials in Pasadena

Diabetic retinopathy is a diabetes complication that affects the blood vessels in the retina and is the leading cause of blindness in working-age adults. Diabetic macular edema (DME) involves fluid accumulation in the macula. Treatment includes anti-VEGF injections, laser therapy, and blood sugar control.

There are currently 4 diabetic retinopathy clinical trials recruiting participants in Pasadena, CALIFORNIA. These studies are seeking a combined 1,188 participants. Research is being sponsored by Jaeb Center for Health Research, Boehringer Ingelheim, Kyowa Kirin Co., Ltd.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Diabetic Retinopathy Clinical Trials in Pasadena — FAQ

Are there diabetic retinopathy clinical trials in Pasadena?

Yes, there are 4 diabetic retinopathy clinical trials currently recruiting in Pasadena, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Pasadena?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Pasadena research site will contact you about next steps.

Are clinical trials in Pasadena free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Pasadena studies also compensate for your time and travel.

What diabetic retinopathy treatments are being tested?

The 4 active trials in Pasadena are testing new therapies including novel drugs, biologics, and treatment approaches for diabetic retinopathy.

Data updated March 2, 2026 from ClinicalTrials.gov